摘要
Prognosis of patients with malignant pleural mesothelioma remains very poor. Single treatment modality is clearly not effective in improving disease-free and overall survival. For this reason combined modality therapy is intensively investigated. In the well-performed and timely systematic review by Cao and colleagues, results of trimodality therapy for mesothelioma consisting of neoadjuvant or adjuvant chemotherapy, extrapleural pneumonectomy and adjuvant radiotherapy, were evaluated （1）. A total of 16 studies were included of which one was a randomized controlled trial, 5 were prospective studies and the others selected retrospective, observational studies. Although the results are inconsistent,
Prognosis of patients with malignant pleural mesothelioma remains very poor. Single treatment modality is clearly not effective in improving disease-free and overall survival. For this reason combined modality therapy is intensively investigated. In the well-performed and timely systematic review by Cao and colleagues, results of trimodality therapy for mesothelioma consisting of neoadjuvant or adjuvant chemotherapy, extrapleural pneumonectomy and adjuvant radiotherapy, were evaluated （1）. A total of 16 studies were included of which one was a randomized controlled trial, 5 were prospective studies and the others selected retrospective, observational studies. Although the results are inconsistent,
